Philip Sharp is listed as a director on 5 SEC Form D filings by 2 issuers between Oct 2014 and Dec 2020: Vir Biotechnology, Inc. (San Francisco, CA — biotechnology — 2018; $250M reported sold to 5 investors) and Syros Pharmaceuticals, Inc. (Cambridge, MA — biotechnology — 2014–2020; $129.8M reported sold to 19 investors).
What this means 2 separate companies raised money with this person listed as director, over about 6 years. Across those companies the filings report $379.8M sold in total.
Listed alongside Nancy Simonian (4 shared filings), Richard A. Young (4 shared filings), Robert Nelsen (4 shared filings), Vicki Sato (4 shared filings), Amir Nashat (3 shared filings) and 28 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Philip. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 7 bankruptcy cases matching the name listed in Key records below.
What this means 7 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 5 public filings for Philip Sharp and found 5 differences: Offering amount changed between filings; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.